Eligibility Criteria
- Patient must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC)
- Patient must have undergone diagnostic chest CT with contrast (unless medically contraindicated) within 42 days prior to randomization.
- Patient must have undergone FDG PET/CT of chest within 90 days prior to randomization.
- Patient must not have evidence of hilar or mediastinal nodal involvement.
- Patient must have undergone history and physical examination within 28 days prior to randomization.
- Patient must not have received any prior treatment for NSCLC.
- Patient must not have undergone prior radiation to overlapping regions of the chest
- Patient must be ≥ 18 years old.
- Patient must have Zubrod Performance Status of 0-2
- Patient must not have myocardial infarction within 90 days prior to randomization.
- Patient must not have a history of clinically significant interstitial lung disease or evidence of active pneumonitis on the screening chest CT.
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized prostate cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.